Abstract P3-13-23: Predicting residual disease in breast conservative surgery after neoadjuvant treatments in breast cancer patients using the margin index tool

2017 ◽  
Author(s):  
IT Rubio ◽  
I Loinaz ◽  
AJ Esgueva-Colmenarejo
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Residual Disease ◽  
Conservative Surgery ◽  
Breast Cancer Patients ◽  
Breast Conservative Surgery

Feasibility of concurrent weekly paclitaxel and radiotherapy in adjuvant treatment of breast cancer: An experience from India.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11536-e11536
Author(s):  
Mohan Kumar Somashekar ◽  
Murali Subramanian V ◽  
Nirmala Srikantaiah S ◽  
Arul Ponni TR ◽  
Rajeev A G ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Conservative Surgery ◽  
Weekly Paclitaxel ◽  
Severe Toxicity ◽  
Breast Cancer Patients ◽  
Skin Reactions ◽  
Breast Conservative Surgery ◽  
Whole Breast Radiotherapy

e11536 Background: Majority of the breast cancer patients require adjuvant radiotherapy and chemotherapy for better locoregional and distant control. However the sequencing of these is still debatable . Hence concurrent chemo radiation may avoid the delay in either of the adjuvant therapies. Anthracyclines are not used concurrently with radiation because of severe toxicity. Hence the current study was taken to assess the feasibility of concurrent weekly paclitaxel and radiotherapy in adjuvant treatment of ca breast. Methods: A prospective study was conducted on 22 breast cancer patients, post modified radical mastectomy or breast conservative surgery from November 2008 to April 2010. Chest wall or whole breast radiotherapy was given on Tele Cobalt or Linac for a dose of 50 – 50.4Gy in conventional fractionation. Boost of 16 Gy was given to tumor cavity with photons or electrons for those undergone breast conservative surgery. All patients received Inj.paclitaxel 60 mg/m2 once a week for 5 weeks. After completion of RT, paclitaxel dose was increased to 80mg/m2 for remaining 7 cycles. This was followed by anthracycline based treatment sequentially as per standard adjuvant guidelines. Patients assessed weekly and toxicities graded based on CTC version 03. The minimum follow up was 2 months after completion of chemoradiation. Chi-Square test and Fisher exact test were used to interpret the results with literature. Results: See table below. Skin reaction was more frequent and severe of all toxicities (p=0.003).With available literatures on adjuvant radiation alone the grade III and higher skin reactions are 3% but in our study it is 28% because of which 5/22 (22%) patients had interruption of both chemotherapy and radiation. Conclusions: Concurrent chemoradiation with weekly paclitaxel in adjuvant treatment of ca breast is associated with more skin reactions which may result in significant treatment interruptions. It should be practiced cautiously which requires further randomized control studies to assess the toxicities in detail. [Table: see text]

Feasibility of concurrent weekly paclitaxel and radiotherapy in node-positive breast cancer: An experience from India.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 201-201
Author(s):  
Mohan Kumar ◽  
Murali Subramanian ◽  
Rajeev AG ◽  
Arul Ponni ◽  
Nirmala S ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Conservative Surgery ◽  
Weekly Paclitaxel ◽  
Adjuvant Radiation ◽  
Breast Cancer Patients ◽  
Skin Reactions ◽  
Breast Conservative Surgery ◽  
Node Positive

201 Background: Breast cancer patients with positive node and extra nodal spread are at a higher risk for distant metastases and they require immediate adjuvant chemotherapy. Similarly patients after breast conservative surgery or with patholgical T3, T4 disease require adjuvant radiation as early as possible. Taxanes have shown good response in node positive patients and are combined in many adjuvant chemotherapy regimens. Hence the current study was taken to assess the feasibility of concurrent weekly paclitaxel and radiotherapy. Methods: A prospective study was conducted on 22 female breast cancer patients after modified radical mastectomy or breast conservative surgery with pathologically positive node. Chest wall or whole breast radiotherapy was given on Tele Cobalt or Linac for a dose of 50 – 50.4Gy in conventional fractionation. Boost of 16 Gy was given to tumor cavity for those undergone breast conservative surgery. All patients received Inj. paclitaxel 60 mg/m2 once a week for 5 weeks. After completion of RT, paclitaxel dose was increased to 80mg/m2 for remaining 7 cycles. This was followed by anthracycline-based treatment sequentially as per standard adjuvant guidelines. Patients assessed weekly and toxicities graded based on CTC version 03. The minimum follow up was 2 months after completion of chemoradiation. Chi-Square test and Fisher exact test were used to interpret the results with literature. Results: See table. Skin reaction was more frequent and severe of all toxicities (p=0.003). With available literatures on adjuvant radiation alone the grade III and higher skin reactions are 3% but in our study it is 28% because of which 5/22 (22%) patients had interruption of both chemotherapy and radiation. Conclusions: Concurrent chemoradiation with weekly paclitaxel in adjuvant treatment of ca breast is associated with more Skin reactions which may result in significant treatment interruptions. It should be practiced cautiously which requires further randomized control studies to assess the toxicities in detail. [Table: see text]

Non Clinical Factors as Determinants of the Use of Breast Conservative Surgery in Italy

2003 ◽  
Vol 89 (2) ◽  
pp. 168-172 ◽  
Author(s):  
◽  
Giampiero Porzio
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Geographic Area ◽  
Conservative Surgery ◽  
Breast Cancer Patients ◽  
Clinical Factors ◽  
Level Of Education ◽  
Multifactorial Analysis ◽  
Breast Conservative Surgery ◽  
Diagnosis Age

The aims of the study were to evaluate the trend of breast conservative surgery (BCS) in Italian breast cancer patients and to identify its nonclinical determinants. Data of 2062 patients surgically treated patients for primary breast cancer were evaluated; 788 (38.0%) had been submitted to breast conservative surgery. A different percentage of breast conservative surgery was found with respect to geographic patient's residence (North, 41.1%; Central, 37.6%; South, 33.0%). Multifactorial analysis showed that time since diagnosis, age at diagnosis and nonclinical factors, such as geographic area of residence and level of education, were significantly associated with breast conservative surgery.

Sign in / Sign up

Export Citation Format

Share Document